Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C65H73Cl2N9O24.ClH |
Molecular Weight | 1471.688 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 18 / 18 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@@]2(O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2OC3=C4OC5=CC=C(C=C5Cl)[C@@H](O)[C@@H](NC(=O)[C@H](N)CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]6C(C=C3OC7=C(Cl)C=C(C=C7)[C@@H](O)[C@@H]8NC(=O)[C@H](NC6=O)C9=CC(=C(O)C=C9)C%10=C(C=C(O)C=C%10O)[C@H](NC8=O)C(O)=O)=C4
InChI
InChIKey=LLWFHCJFZGXUAT-UMXPSMRGSA-N
InChI=1S/C65H73Cl2N9O24.ClH/c1-22(2)11-33(68)57(87)75-48-50(82)25-6-9-37(31(66)13-25)96-39-15-27-16-40(54(39)100-64-55(53(85)52(84)41(21-77)98-64)99-43-20-65(4,70)56(86)23(3)95-43)97-38-10-7-26(14-32(38)67)51(83)49-62(92)74-47(63(93)94)30-17-28(78)18-36(80)44(30)29-12-24(5-8-35(29)79)45(59(89)76-49)73-60(90)46(27)72-58(88)34(19-42(69)81)71-61(48)91;/h5-10,12-18,22-23,33-34,41,43,45-53,55-56,64,77-80,82-86H,11,19-21,68,70H2,1-4H3,(H2,69,81)(H,71,91)(H,72,88)(H,73,90)(H,74,92)(H,75,87)(H,76,89)(H,93,94);1H/t23-,33+,34-,41+,43-,45+,46+,47-,48+,49-,50+,51+,52+,53-,55+,56+,64-,65-;/m0./s1
Molecular Formula | C65H73Cl2N9O24 |
Molecular Weight | 1435.227 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 18 / 18 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Norvancomycin is an analog of glycopeptide antibiotic vancomycin. It was first found to be produced by a soil microorganisms such Nocardia orientalis and Amycolatopsis orientalis and recently was found in actinomycete Amycolatopsis orientalis CPCC200066. Norvancomycin can be derived by demethylation at N-terminus of vancomycin. It has significant inhibitory activity against Gram-positive cocci and bacilli. The mode of action of norvancomycin is based on its ability to bind to the cell-wall peptidoglycan of Gram-positive bacteria terminating tripeptide -L-Lys-D-Ala-D-Ala. Similar to vancomycin in terms of antibacterial activity, spectrum and clinical efficacy norvancomycin has more potent antibiotic activity against Staphylococcus aureus and higher affinity for bacteria cell wall analogue DALAA than vancomycin. Norvancomycin has been widely used in China to treat endocarditis, osteomyelitis and other severe infections caused by Staphylococcus aureus (including methicillin-resistant strains). The adverse drug reactions of norvancomycin are like vancomycin, such as nephrotoxicity, ototoxicity, rash and itching. Norvancomycin is not available therapeutically outside of China.
CNS Activity
Originator
Curator's Comment: Norvancomycin was first isolated from Van-23, a strain of Amycolatopsis orientalis from soil sample collected in Guizhou Province, China, in 1959 and has been clinically used in China since 1967. In the early 1980s it was found to be produced by a soil isolate collected in Yucatan, Mexico and its structure was determined by scientists at Eli Lilly.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: map00550 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9766467 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Unknown Approved UseStaphylococcus aureus infections |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27738856
Patients after craniotomy with an indwelling catheter in the operational area/ventricle were administered norvancomycin by two approaches: (1) The conventional group consisted of 14 cases that were infused with 0.8 g norvancomycin for 1 h, every 12 h; (2) The continuous administration group consisted of 14 cases that were infused with 0.8 g norvancomycin for 1 h, and then another 0.4 g for 11 h with extended infusion, followed by continuous infusion of 0.4 g norvancomycin for 12 h.
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:12:20 GMT 2023
by
admin
on
Sat Dec 16 10:12:20 GMT 2023
|
Record UNII |
OV842925ZC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000126107
Created by
admin on Sat Dec 16 10:12:20 GMT 2023 , Edited by admin on Sat Dec 16 10:12:20 GMT 2023
|
PRIMARY | |||
|
198774-23-1
Created by
admin on Sat Dec 16 10:12:20 GMT 2023 , Edited by admin on Sat Dec 16 10:12:20 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
213997-73-0
Created by
admin on Sat Dec 16 10:12:20 GMT 2023 , Edited by admin on Sat Dec 16 10:12:20 GMT 2023
|
PRIMARY | |||
|
SUB32950
Created by
admin on Sat Dec 16 10:12:20 GMT 2023 , Edited by admin on Sat Dec 16 10:12:20 GMT 2023
|
PRIMARY | |||
|
OV842925ZC
Created by
admin on Sat Dec 16 10:12:20 GMT 2023 , Edited by admin on Sat Dec 16 10:12:20 GMT 2023
|
PRIMARY | |||
|
92044444
Created by
admin on Sat Dec 16 10:12:20 GMT 2023 , Edited by admin on Sat Dec 16 10:12:20 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |